Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors

Erbilgin, Yücel; Eskazan, Ahmet Emre; Ongoren, Seniz; Ar, Muhlis Cem; Baslar, Zafer; Soysal, Teoman; Sayitoğlu, Müge; Özbek, Uğur; Hatırnaz, Ng Özden; Salihoglu, Ayse; Elverdi, Tugrul; Fırtına, Sinem; Tasar, Orcun; MERCAN, SEVCAN; Sisko, Sinem; Khodzhaev, Khusan

doi:10.1080/10428194.2018.1473573

Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors

Yazarlar
Yücel Erbilgin Türkiye
Ahmet Emre Eskazan Türkiye
Ng Özden Hatırnaz Türkiye
Ayse Salihoglu Türkiye
Tugrul Elverdi Türkiye
Sinem Fırtına İstinye Üniversitesi, Türkiye
Orcun Tasar Türkiye
Dr. Öğr. Üyesi Sevcan MERCAN Kurum Bilgileri Tıp Fakültesi Dahili Tıp Bilimleri Tıbbi Genetik Özgeçmiş Sayfası İletişim Bilgileri: (000)000-0000 Kafkas Üniversitesi, Türkiye
Sinem Sisko Türkiye
Khusan Khodzhaev Türkiye
Seniz Ongoren Türkiye
Muhlis Cem Ar İstanbul Üniversitesi-Cerrahpaşa, Türkiye
Zafer Baslar Türkiye
Teoman Soysal İstanbul Üniversitesi-Cerrahpaşa, Türkiye
Müge Sayitoğlu İstanbul Üniversitesi, Türkiye
Uğur Özbek Acıbadem Mehmet Ali Aydınlar Üniversitesi, Türkiye

Özet

Tyrosine kinase inhibitor (TKI) therapy is the current treatment of choice for patients with chronic phase chronic myeloid leukemia (CML) leading to rapid and durable hematological as well as molecular responses. However, emergence of resistance to TKIs has been the major obstacle to treatment success on long term. In this regard kinase domain mutations are the most common mechanism of therapy failure. In this study, we analyzed peripheral blood samples from 17 CML patients who had developed resistance to various TKIs by using next-generation sequencing parallel to Sanger sequencing. BCR-ABL1 kinase domain mutations have been found in 59% of the cohort. Our results demonstrate that next-generation sequencing results in a higher mutational detection rate than reported with conventional sequencing methodology. Furthermore, it showed the clonal diversity more accurately.

Anahtar Kelimeler

Chronic myeloid leukemia | drug resistance | next-generation sequencing | tyrosine kinase inhibitor

Makale Türü	Özgün Makale
Makale Alt Türü	SSCI, AHCI, SCI, SCI-Exp dergilerinde yayımlanan tam makale
Dergi Adı	Leukemia Lymphoma
Dergi ISSN	1042-8194
Dergi Tarandığı Indeksler	SCI-Expanded
Dergi Grubu	Q2
Makale Dili	İngilizce
Basım Tarihi	01-2019
Cilt No	60
Sayı	1
Sayfalar	200 / 207
Doi Numarası	10.1080/10428194.2018.1473573

BM Sürdürülebilir Kalkınma Amaçları

Atıf Sayıları
SCOPUS	13

Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors

Akademisyenler > Sevcan MERCAN > Yayın Detayı

Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors

Paylaş